| Home | Search | Study Topics | Glossary |
|
|
|
 |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Emory University |
| Information provided by: | Emory University |
| ClinicalTrials.gov Identifier: | NCT00209131 |
Purpose
The majority of kidney stones are treated with shock wave lithotripsy (SWL). We are examining if the medication Flomax will result in improved stone passage rates following SWL.
| Condition |
|
Urolithiasis |
| ChemIDplus related topics: | Tamsulosin Tamsulosin hydrochloride |
| Study Type: | Observational |
| Study Design: | Longitudinal, Defined Population, Prospective Study |
| Official Title: | Efficacy of Flomax to Improve Stone Passage Following Shock Wave Lithotripsy |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Contacts and Locations| Contact: Kenneth Ogan, MD | 404-778-3038 | kenneth_ogan@emoryhealthcare.org |
| United States, Georgia | |||||
| Emory University | Recruiting | ||||
| Atlanta, Georgia, United States, 30322 | |||||
| Contact: Kenneth Ogan, MD 404-778-3038 kenneth_ogan@emoryhealthcare.org | |||||
| Emory University |
| Principal Investigator: | Kenneth Ogan, MD | Emory University |
More Information
| Study ID Numbers: | IRB ID: 128-2005 |
| First Received: | September 14, 2005 |
| Last Updated: | February 7, 2006 |
| ClinicalTrials.gov Identifier: | NCT00209131 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
